Insights
Insights From Our Experts
Articles
Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling
In the fast-paced world of pharmaceuticals, where market forecasting and regulatory compliance are paramount, data-driven insights can make all the difference. Discover how EVERSANA’s Specialty Consulting team excels in crafting tailored predictive modeling solutions for pharmaceutical…
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs The Institute for Clinical and Economic Review (ICER) has recently updated its protocol for assessing unsupported price increases of prescription drugs. This initiative provides…
Sound Off on Interoperability – Leveraging Next-Gen Tech for Enhanced Electronic Benefit Verification and Prior Authorizations to Streamline Workflow
The theme of a recent panel at Access USA was “Technology: the Good, the Bad, and the Ugly.” While serving as an instrument for addressing challenges, technological progress can also introduce new complexities. Watch the recording…
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
EVERSANA’s Value and Evidence (V&E) team grew their global Health Economics & Outcomes Research (HEOR) leadership footprint in early 2024 with the addition of Monique Martin, Pamela Vo and Deepika Thakur, showcasing EVERSANA’s growing global life…
Unlocking Insights: EVERSANA’s Value & Evidence Team’s Impact on Economic and Healthcare Resource Utilization Outcomes in Robotic vs. Manual Total Knee Arthroplasty
The use of robotics in surgical procedures is becoming increasingly popular, with the potential to reshape the landscape of modern surgery. In total knee arthroplasty (TKA), the increased adoption of robotics has improved clinical outcomes, including…
Pioneering the Path: How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies
Early involvement of Medical Affairs in the product lifecycle is not just beneficial – it is mission critical. In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies,…
Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare
Authors: Prachi Singh, Senior Consultant; Robin Arnold, EVP, APAC Consulting Unlock the future of healthcare with our white paper, “Establishing the Pricing and Value Proposition of AI/MedTech Solutions in Healthcare.” Discover the essential components of pricing…
Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact
The oncology market is experiencing rapid growth, driven by innovations in therapies like biomarker-directed and cell-and-gene therapies. These advancements contribute to improved overall and progression-free survival in various cancer types. However, challenges arise from accelerated approvals…
Navigating the Frontier: Generative AI Revolutionizing Healthcare and Life Sciences
In the dynamic landscape of healthcare and life sciences, the integration of cutting-edge technologies has become paramount. Among these innovations, Artificial Intelligence (AI) stands out as a transformative force, reshaping everything from drug discovery to patient…
Harnessing the Commercial Promise of Prescription Drug Use-Related Software (PDURS)
Posted by
John Kutz , Martin Culjat, PhD , Justin Averback , Calvin Fujimoto , Joey Pecoraro on March 7, 20243/7/24
The FDA’s draft guidance on Prescription Drug Use-Related Software (PDURS) offers pharmaceutical manufacturers a novel strategy to enhance a drug’s label by enabling an HCP to prescribe software alongside the drug at the HCP’s discretion. The…